Vita Coco's Strong Q1 2026 Growth Fails to Justify Stretched Valuation

What happened

Vita Coco reported Q1 2026 revenue of $180M, up 37% YoY, with gross margins improving to 40% and management raising full-year guidance. International expansion, particularly in Europe, has been a key growth driver, and the company maintains a robust balance sheet with no long-term debt. However, the stock still trades at roughly 44x trailing earnings, a premium that leaves little room for error. While execution has been strong, structural risks from tariffs, category maturation, and competition persist. The elevated multiple suggests that much of the good news is already priced in, limiting upside potential.

Implication

The strong operational momentum and cash-rich balance sheet provide a cushion, but the stock's 44x P/E ratio already capitalizes several years of growth. Investors should wait for a larger margin of safety or evidence that margin recovery can be sustained despite tariff headwinds before adding positions. A pullback toward $40 or below would improve the risk/reward profile.

Thesis delta

The latest quarter shows that Vita Coco's branded growth and margin recovery are on track, partially easing near-term operational fears. However, this positive data does not change the core valuation concern — the stock still trades at a significant premium to its intrinsic value. The sell bias remains appropriate, as the risk of tariff and competitive pressures is not yet discounted.